1. Home
  2. PHGE vs PMCB Comparison

PHGE vs PMCB Comparison

Compare PHGE & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHGE
  • PMCB
  • Stock Information
  • Founded
  • PHGE 2015
  • PMCB 1996
  • Country
  • PHGE Israel
  • PMCB United States
  • Employees
  • PHGE N/A
  • PMCB N/A
  • Industry
  • PHGE Biotechnology: Pharmaceutical Preparations
  • PMCB Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PHGE Health Care
  • PMCB Health Care
  • Exchange
  • PHGE Nasdaq
  • PMCB Nasdaq
  • Market Cap
  • PHGE 13.3M
  • PMCB 10.9M
  • IPO Year
  • PHGE N/A
  • PMCB N/A
  • Fundamental
  • Price
  • PHGE $0.74
  • PMCB $1.66
  • Analyst Decision
  • PHGE Strong Buy
  • PMCB
  • Analyst Count
  • PHGE 2
  • PMCB 0
  • Target Price
  • PHGE $13.50
  • PMCB N/A
  • AVG Volume (30 Days)
  • PHGE 106.9K
  • PMCB 15.0K
  • Earning Date
  • PHGE 11-14-2024
  • PMCB 12-13-2024
  • Dividend Yield
  • PHGE N/A
  • PMCB N/A
  • EPS Growth
  • PHGE N/A
  • PMCB N/A
  • EPS
  • PHGE N/A
  • PMCB 0.74
  • Revenue
  • PHGE N/A
  • PMCB N/A
  • Revenue This Year
  • PHGE N/A
  • PMCB N/A
  • Revenue Next Year
  • PHGE N/A
  • PMCB N/A
  • P/E Ratio
  • PHGE N/A
  • PMCB $2.23
  • Revenue Growth
  • PHGE N/A
  • PMCB N/A
  • 52 Week Low
  • PHGE $0.48
  • PMCB $1.39
  • 52 Week High
  • PHGE $8.55
  • PMCB $2.58
  • Technical
  • Relative Strength Index (RSI)
  • PHGE 54.77
  • PMCB 51.59
  • Support Level
  • PHGE $0.54
  • PMCB $1.58
  • Resistance Level
  • PHGE $0.80
  • PMCB $1.80
  • Average True Range (ATR)
  • PHGE 0.09
  • PMCB 0.10
  • MACD
  • PHGE 0.02
  • PMCB 0.01
  • Stochastic Oscillator
  • PHGE 64.92
  • PMCB 53.35

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Share on Social Networks: